13,276 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Tobam

Tobam acquired a new stake in Incyte Co. (NASDAQ:INCYFree Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 13,276 shares of the biopharmaceutical company’s stock, valued at approximately $878,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Deseret Mutual Benefit Administrators raised its stake in shares of Incyte by 37.1% during the 2nd quarter. Deseret Mutual Benefit Administrators now owns 606 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 164 shares in the last quarter. Moody National Bank Trust Division raised its position in Incyte by 1.3% during the second quarter. Moody National Bank Trust Division now owns 14,199 shares of the biopharmaceutical company’s stock valued at $861,000 after acquiring an additional 179 shares in the last quarter. Ballentine Partners LLC grew its position in Incyte by 4.0% in the second quarter. Ballentine Partners LLC now owns 4,727 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 182 shares in the last quarter. 180 Wealth Advisors LLC grew its position in Incyte by 4.5% in the first quarter. 180 Wealth Advisors LLC now owns 4,764 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 204 shares in the last quarter. Finally, Empirical Finance LLC raised its holdings in shares of Incyte by 3.7% during the 1st quarter. Empirical Finance LLC now owns 6,395 shares of the biopharmaceutical company’s stock valued at $364,000 after purchasing an additional 230 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling at Incyte

In other Incyte news, insider Thomas Tray sold 572 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the transaction, the insider now directly owns 24,825 shares of the company’s stock, valued at $1,562,485.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Incyte news, insider Thomas Tray sold 572 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.94, for a total value of $36,001.68. Following the transaction, the insider now directly owns 24,825 shares of the company’s stock, valued at $1,562,485.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Barry P. Flannelly sold 1,306 shares of Incyte stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $64.19, for a total value of $83,832.14. Following the sale, the executive vice president now directly owns 58,042 shares of the company’s stock, valued at $3,725,715.98. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,899 shares of company stock worth $1,736,746 over the last ninety days. Insiders own 17.50% of the company’s stock.

Analyst Ratings Changes

INCY has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on shares of Incyte from $59.00 to $61.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Citigroup boosted their target price on Incyte from $80.00 to $88.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Royal Bank of Canada reiterated a “sector perform” rating and set a $67.00 price target on shares of Incyte in a report on Tuesday, September 3rd. Truist Financial restated a “hold” rating and issued a $74.00 price objective (down from $83.00) on shares of Incyte in a research note on Wednesday, September 18th. Finally, BMO Capital Markets reiterated an “underperform” rating and issued a $48.00 target price (down from $52.00) on shares of Incyte in a research note on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $73.21.

Get Our Latest Stock Analysis on INCY

Incyte Stock Down 1.0 %

Shares of NASDAQ:INCY traded down $0.66 during mid-day trading on Thursday, reaching $65.10. 428,447 shares of the stock were exchanged, compared to its average volume of 2,394,779. The company has a market cap of $14.62 billion, a P/E ratio of 19.62, a P/E/G ratio of 5.17 and a beta of 0.73. The stock’s 50 day simple moving average is $64.25 and its 200-day simple moving average is $60.45. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Incyte Co. has a one year low of $50.27 and a one year high of $70.36.

Incyte (NASDAQ:INCYGet Free Report) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the consensus estimate of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company posted $0.77 earnings per share. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. As a group, equities research analysts predict that Incyte Co. will post 0.66 EPS for the current year.

Incyte Profile

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Read More

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.